Clinical Trials Logo

Chronic Hepatitis C clinical trials

View clinical trials related to Chronic Hepatitis C.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05138523 Completed - Chronic Hepatitis c Clinical Trials

Evaluation of the Efficacy and Safety of the Fixed-dose Combination Sofosdac® 400mg/60mg in Patients With Chronic Hepatitis C (HCV)

Start date: November 21, 2019
Phase:
Study type: Observational

A multicentric, observational, open-design study conducted to evaluate the efficacy and safety of Sofosdac® 400mg/60mg tablets treatment in 100 patients with chronic hepatitis C (HCV)

NCT ID: NCT04695769 Completed - Chronic Hepatitis C Clinical Trials

Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders

Start date: November 21, 2020
Phase: Phase 4
Study type: Interventional

This study aims to assess the role of ribavirin as an adjuvant to sofosbuvir/velpatasvir/voxilaprevir combination in retreatment of chronic hepatitis C with previous treatment failure.

NCT ID: NCT04391985 Completed - Clinical trials for Chronic Hepatitis C Virus Infection

Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients

Start date: March 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

enrolled participants were treated orally with SOF plus a fixed dose combination of OBV/PTV/r plus RBV.

NCT ID: NCT04387539 Completed - Clinical trials for Chronic Hepatitis C Virus Infection

ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants

Start date: March 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Experienced participants who had HCV GT4 infection were treated with Sofosbuvir/Simeprevir/Daclatasvir/Ribavirin (SOF/SMV/DCV/RBV)

NCT ID: NCT04387526 Completed - Clinical trials for Chronic Hepatitis C Virus Infection

Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4

Start date: April 1, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

This study aims to evaluate the efficacy and safety of DCV plus sofosbuvir (SOF) with or without ribavirin (RBV) for treatment of Egyptian participants infected with HCV GT4.

NCT ID: NCT04385407 Completed - Clinical trials for Chronic Hepatitis C Virus Infection

Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients

Start date: April 2015
Phase: Phase 2
Study type: Interventional

A total of 201 participants with chronic HCV GT4 infection were allocated into two groups. One group participants were treated with SOF plus RBV (24 weeks). The second group was treated with SOF plus SMV (12 weeks).

NCT ID: NCT04382937 Completed - Clinical trials for Chronic Hepatitis C Virus Infection

Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection

Start date: January 12, 2016
Phase: Phase 3
Study type: Interventional

Primary objective: To demonstrate non-inferiority in sustained virologic response (SVR, undetectable HCV RNA at Follow up week 12) between PEG-Intron 1.5 µg per kg SC Q1W + Ribavirin 800-1400 mg PO daily and P1101 400 µg SC Q2W + Ribavirin 800-1400 mg PO daily for the treatment of chronic HCV genotype 2 infection

NCT ID: NCT04232514 Completed - Chronic Hepatitis C Clinical Trials

Drug-drug Interaction Study Between HEC74647PA Capsule and HEC110114 Tablets in Healthy Subjects

Start date: July 15, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the drug-drug-interaction (DDI), pharmacokinetics (PK) and tolerability of HEC74647 combined with HEC110114 in healthy subjects

NCT ID: NCT04202952 Completed - Chronic Hepatitis C Clinical Trials

The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects

HEC110114
Start date: July 6, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase Ib/IIa, Single Center, Randomized, open, Sofosbuvir-controlled, Multiple Ascending Dose Study to Access the Tolerability,Pharmacokinetics and Pharmacodynamics of HEC110114 Tablets in HCV-infected Subjects

NCT ID: NCT04201275 Completed - Chronic Hepatitis C Clinical Trials

The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC74647 in HCV-infected Subjects

Start date: December 18, 2019
Phase: Phase 1
Study type: Interventional

The goal of this study is to assess the tolerability, pharmacokinetics and antiviral activity of HEC74647 in HCV treatment naïve subjects with genotypes 1-6.